Astrazeneca Plc $AZN Shares Bought by Rehmann Capital Advisory Group

Rehmann Capital Advisory Group grew its holdings in Astrazeneca Plc (NYSE:AZN) by 46.9% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 10,283 shares of the company’s stock after buying an additional 3,282 shares during the period. Rehmann Capital Advisory Group’s holdings in Astrazeneca were worth $1,950,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the business. Triumph Capital Management purchased a new stake in Astrazeneca during the 3rd quarter valued at approximately $25,000. MV Capital Management Inc. purchased a new position in shares of Astrazeneca in the 4th quarter valued at approximately $26,000. Mascoma Wealth Management LLC acquired a new position in shares of Astrazeneca in the first quarter valued at approximately $26,000. Roxbury Financial LLC acquired a new position in shares of Astrazeneca in the second quarter valued at approximately $29,000. Finally, Reflection Asset Management purchased a new stake in shares of Astrazeneca during the fourth quarter worth approximately $31,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Astrazeneca Stock Up 0.2%

Astrazeneca stock opened at $162.43 on Wednesday. The stock’s 50 day moving average price is $170.58 and its 200 day moving average price is $184.42. Astrazeneca Plc has a 1-year low of $145.79 and a 1-year high of $212.71. The company has a market cap of $251.91 billion, a PE ratio of 24.28, a price-to-earnings-growth ratio of 1.27 and a beta of 0.25. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.89 and a quick ratio of 0.67.

Astrazeneca (NYSE:AZN) last released its quarterly earnings data on Monday, July 27th. The company reported $2.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.50 by $0.13. The firm had revenue of $15.38 billion during the quarter, compared to analysts’ expectations of $15.44 billion. Astrazeneca had a return on equity of 31.45% and a net margin of 17.02%.Astrazeneca’s revenue was up 6.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.17 earnings per share. On average, sell-side analysts predict that Astrazeneca Plc will post 10.19 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Astrazeneca in a report on Tuesday, June 30th. Weiss Ratings cut shares of Astrazeneca from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, July 28th. Jefferies Financial Group restated a “buy” rating on shares of Astrazeneca in a research report on Friday, June 26th. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Astrazeneca in a research note on Tuesday, June 30th. Finally, Barclays reiterated a “buy” rating on shares of Astrazeneca in a research note on Monday, June 1st. Thirteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $206.67.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.